Sionna Therapeutics (NASDAQ:SION) Trading Up 3.8% – Here’s What Happened

Sionna Therapeutics, Inc. (NASDAQ:SION)’s stock price traded up 3.8% on Friday . The stock traded as high as $36.78 and last traded at $36.8540. 52,793 shares changed hands during mid-day trading, a decline of 81% from the average session volume of 280,808 shares. The stock had previously closed at $35.49.

Analysts Set New Price Targets

Several analysts have issued reports on SION shares. Royal Bank Of Canada reaffirmed an “underperform” rating and set a $24.00 price target on shares of Sionna Therapeutics in a research report on Monday, December 1st. Weiss Ratings reissued a “sell (e+)” rating on shares of Sionna Therapeutics in a research report on Monday, December 29th. UBS Group restated a “buy” rating on shares of Sionna Therapeutics in a research note on Monday, March 2nd. Citizens Jmp started coverage on shares of Sionna Therapeutics in a report on Tuesday, February 24th. They issued a “market outperform” rating and a $63.00 target price on the stock. Finally, Lifesci Capital upgraded shares of Sionna Therapeutics to a “strong-buy” rating in a research note on Wednesday, February 25th. Two equities research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, Sionna Therapeutics has an average rating of “Moderate Buy” and an average target price of $50.57.

Sionna Therapeutics Stock Performance

The firm has a market capitalization of $1.64 billion and a price-to-earnings ratio of -18.66. The business has a fifty day moving average of $38.18 and a two-hundred day moving average of $36.35.

Sionna Therapeutics (NASDAQ:SION) last posted its quarterly earnings results on Monday, March 2nd. The company reported ($0.46) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.61) by $0.15.

Insider Buying and Selling at Sionna Therapeutics

In other news, major shareholder Tpg Gp A, Llc sold 250,000 shares of the stock in a transaction dated Thursday, January 22nd. The shares were sold at an average price of $40.00, for a total value of $10,000,000.00. Following the transaction, the insider directly owned 6,494,962 shares of the company’s stock, valued at $259,798,480. This represents a 3.71% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Orbimed Advisors Llc sold 33,356 shares of the firm’s stock in a transaction dated Wednesday, December 24th. The stock was sold at an average price of $44.55, for a total transaction of $1,486,009.80. Following the sale, the director owned 3,561,655 shares of the company’s stock, valued at approximately $158,671,730.25. This represents a 0.93% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 378,618 shares of company stock worth $15,731,751 over the last ninety days. Insiders own 3.90% of the company’s stock.

Institutional Investors Weigh In On Sionna Therapeutics

Several hedge funds have recently bought and sold shares of the stock. Braidwell LP bought a new stake in shares of Sionna Therapeutics during the second quarter worth approximately $18,770,000. Eventide Asset Management LLC bought a new position in shares of Sionna Therapeutics during the fourth quarter worth approximately $26,290,000. Vanguard Group Inc. increased its stake in shares of Sionna Therapeutics by 81.4% during the third quarter. Vanguard Group Inc. now owns 1,143,154 shares of the company’s stock worth $33,620,000 after purchasing an additional 512,803 shares during the period. State Street Corp lifted its holdings in Sionna Therapeutics by 188.7% during the 4th quarter. State Street Corp now owns 693,395 shares of the company’s stock worth $28,526,000 after purchasing an additional 453,196 shares during the last quarter. Finally, Viking Global Investors LP lifted its holdings in Sionna Therapeutics by 8.2% during the 2nd quarter. Viking Global Investors LP now owns 3,195,181 shares of the company’s stock worth $55,436,000 after purchasing an additional 242,427 shares during the last quarter.

Sionna Therapeutics Company Profile

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.